Assessment of the Natural Antibody Response to Pneumococcal Surface Proteins During Acute Otitis Media in Children
NCT01214538 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2011-09-27
Summary
This clinical study is designed to assess prospectively the sero-responses to various proteins in cases of pneumococcal Acute Otitis Media.
Conditions
- Acute Otitis Media
Sponsors & Collaborators
-
NasVax Ltd
lead INDUSTRY
Principal Investigators
-
Ron Dagan, Prof. MD. · Ben-Gurion University of the Negev
Eligibility
- Min Age
- 3 Months
- Max Age
- 3 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-10-31
- Primary Completion
- 2014-03-31
- Completion
- 2014-07-31
Countries
- Israel
Study Locations
More Related Trials
-
Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage
NCT01109108 ·Status: COMPLETED
-
A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)
NCT01215188 ·Status: COMPLETED ·Phase: PHASE2
-
Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers
NCT02146365 ·Status: COMPLETED
-
A Study to Learn About How a New Pneumococcal Vaccine Works in Children
NCT06531538 ·Status: COMPLETED ·Phase: PHASE2
-
Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life
NCT01735084 ·Status: COMPLETED ·Phase: PHASE4
-
Study Evaluating the Nasopharyngeal Carriage in Healthy Children
NCT00768833 ·Status: COMPLETED
-
Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A
NCT00839254 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media
NCT00195611 ·Status: COMPLETED
-
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers
NCT01485406 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age
NCT05489328 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)
NCT01215175 ·Status: COMPLETED ·Phase: PHASE1
-
Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease
NCT01128439 ·Status: COMPLETED
-
Impact of Pneumococcal Conjugate Vaccines on Otitis Media and Acute Otitis Media in Swedish Children
NCT02742753 ·Status: COMPLETED
-
Immune Memory Evaluation in Children Following a Primary Vaccination With Pneumococcal Conjugate Vaccines.
NCT00333450 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults
NCT04830358 ·Status: COMPLETED ·Phase: PHASE1
-
Nasopharyngeal Carriage of S. Pneumoniae
NCT04460313 ·Status: RECRUITING ·Phase: NA
-
V114 and Acute Otitis Media (V114-032/PNEU-ERA)
NCT04193215 ·Status: COMPLETED ·Phase: PHASE3
-
A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria
NCT01193582 ·Status: COMPLETED ·Phase: PHASE4
-
PCV13 in Non-pregnant Papua New Guinean Women
NCT04183322 ·Status: COMPLETED
-
A Study to Assess the Impact of Pneumococcal Conjugate Vaccination Programme on the Carriage of Pneumococci
NCT01040143 ·Status: COMPLETED
-
Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children
NCT01545375 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating Vaccine Responses in Healthy Infants Receiving Their Routine Primary Immunisation According to the Accelerated United Kingdom Schedule at 2, 3 and 4 Months
NCT01425372 ·Status: COMPLETED
-
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13
NCT05934890 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage
NCT01311024 ·Status: COMPLETED
-
National Trends in Otitis Media in Children Under 5 Years of Age
NCT01339546 ·Status: COMPLETED